New developments in laboratory monitoring of HIV-1 infection  by Telenti, A.
REVIEW
New developments in laboratory monitoring of HIV-1 infection
A. Telenti
Division of Infectious Diseases and Institute of Microbiology, Center Hospitalier
UniversitaireVaudois, Lausanne, Switzerland
The laboratory tests currently available to the clinician for day-to-day management of
HIV infection are generally limited to the measurement of the viral load and of the CD4
cell count. More recently, analysis of drug resistance and of plasma drug levels have been
added to the monitoring armamentarium. There are, however, numerous other techni-
ques currently available to researchers that may in the future be incorporated into clinical
routine. These include the analysis of human and viral genetic determinants of disease
evolution, detailed analyses of immune recovery and reserve, pharmacogenetic deter-
minants of treatment response, and toxicity. These approaches may in the future provide
highly individualized disease management.
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The decision to initiate antiretroviral therapy
(ART) is currently based on the evaluation of
the progression of the HIV-1 infection as estimated
by viral load and CD4 cell count measurements
[1,2]. While these two parameters have proven
very useful, they may not allow for a precise
individualization of treatment decisions. In this
context, there is an increasing number of techni-
ques in development that could help such indivi-
dualized management of the patient. An idealized
implementation of novel techniques is presented
in Figure 1, and discussed in the present review.
H U M A N G E N E T I C S A N D
S U S C E P T I B I L I T Y T O
H I V - 1 I N F E C T I O N
Knowledge on the human genome is advancing
rapidly, and management of HIV should take full
advantage of this new information. HIV is char-
acterized by a wide spectrum of host response to
the infection, to treatment (failure and toxicity),
and to vaccination. There are already multiple
alleles recognized to play a role in HIV disease
(Table 1), and new genes are on the way to being
identified. Most polymorphisms can be detected
by allele-specific PCR using closed-tube fluores-
cent technology such as TaqMan or LightCycler, at
limited cost. While the analysis of human suscept-
ibility to HIV remains in the area of research, it is
possible that future decisions regarding the best
time to initiate therapy may be based on particular
genotype profiles. Once ART has been initiated,
CCR5 D32 heterozygosity has been shown to have
a modest influence on treatment response [3–6].
I N F L U E N C E O F V I R A L G E N E T I C
C H A R A C T E R I S T I C S O N D I S E A S E
P R O G R E S S I O N
Not only human genetics may modify HIV disease
progression. HIV viruses display a spectrum of
infectivity and replication phenotypes, as illu-
strated by the diversity of phenotypes of wild-type
isolates (Figure 2) [7,8]. Polymorphisms through-
out the viral genome, genetic defects such as nat-
ural deletion of nef, or shifts in receptor usage, may
lead to in vivo or in vitro changes in growth
phenotype [9–12]. The methods for assessing this
variable are generally reserved for the research
setting; however, they may become progressively
available for clinical use [13]. It is unclear how and
in which setting this information may become
useful in the routine management of patients.
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One piece of viral genetic information that is
increasingly being made available to clinicians is
the viral subtype. Although subtype analysis
was previously performed by sequence analysis
of the viral env gene, subtype information is
now generally derived from pol sequences
generated at the time of genotypic resistance test-
ing. There are useful websites for determining
the viral subtype on-line (www.ncbi.nlm.nih.
gov/retroviruses/subtype/subtype.html), and for
downloading programs for precise identification
of recombinant variants, such as Simplot (www.
med.jhu.edu/deptmed/sray/download/) [14].
The entry and expansion of specific viral clones,
indicating epidemic clusters or potentially highly
transmissible strains, can be assessed from analy-
sis of sequence data sets using phylogenetic pro-
grams [15]. There is insufficient evidence to link
specific subtypes to clinical outcome.
D E T E C T I O N O F R E S I D U A L V I R A L
R E P L I C A T I O N
Eradication of HIV with potent ART is not feasible,
because of the existence of a reservoir of laten-
tly infected cells [16,17]. HIV transcription may
persist in peripheral blood mononuclear cells
(PBMCs) of subjects with less than 50 plasma
Figure 1 An idealized implementation of novel techniques
in the management of HIV-infected patients.
Table 1 Genes that influence progression of HIV
Gene and allele
Influence on
progression Reference
CCR5 [42]
CCR5þ/delta 32 Slow
CCR5 promoter P1/P1 Rapid
CCR2 [43]
CCR2þ/64I Slow
SDF1 [44]
SDF1 30A/30A Slow
IL-10 [45]
IL-10þ/50A or IL-10 50A/50A Rapid
Class I HLA genes [46,47]
HLA-A, B and C
heterozygosity
Slow
HLA-B35 Rapid
HLA-Cw04 Rapid
CX3CR1 [48]
CX3CR1 I249M280 Rapid
RANTES [49]
-403A Slow
Figure 2 Infectivity and replication
of wild-type clinical HIV-1 isolates
(adapted from Kaufman et al. [7]).
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RNA copies/mL [18]. Transient viral load eleva-
tion can be observed after non-specific T-cell
activation by antigenic stimuli such as influ-
enza vaccine and tetanus toxoid [19,20]. While
ongoing replication can be associated with gene-
tic evolution, and possibly with selection of
resistance mutations, viral escape in the presence
of antiretroviral pressure may also result in the
paradoxical phenomenon of ‘wild-type’ viral
rebound [21].
Routine assessment of viral load in peripheral
blood uses the ‘less than 400’ or ‘less than 20–50’
RNA copy level. There is still debate on the sig-
nificance of viremia between 20 and 400 copies.
A recent report [22], and data from the Swiss
HIV Cohort and the Frankfurt Clinic Cohort, iden-
tified a high incidence of low-level viral rebound
(37.4/100 persons per year). Episodes of viral
rebound in the range of 51–100 copies/mL will
probably resolve spontaneously, and the occur-
rence of blips—self-limited episodes of low-level
viral rebound—may not carry a negative prog-
nosis for the durability of viral suppression. These
data should influence decisions regarding the
most appropriate delay for re-assessment of
HIV viral load, assessment of treatment adher-
ence, and monitoring of plasma drug levels and
viral resistance.
However, in understanding the nature of blips,
clinicians should be aware of the variability of the
ultrasensitive amplification methods. Inter-assay
and intra-assay coefficient variabilities of up to
35.4% and 40%, respectively, have been reported
for this assay [23]. In addition, the high sensitivity
of ultrasensitive modified methods increases the
risk of PCR contamination.
M E A S U R I N G A N D I N T E R P R E T I N G
D R U G R E S I S T A N C E
Virologic failure is observed in 20–40% of indivi-
duals receiving ART [24]; hence the interest in
providing resistance data to clinicians. Both geno-
typic (identification of drug resistance mutations)
and phenotypic (growth phenotype in the pre-
sence of drug) techniques are available [25] (Figure
3). The creation of a large correlational geno-phe-
notype database has allowed development of the
‘virtual phenotype’ [26]. However, resistance test-
ing remains complex, expensive, and, in the case of
genotypic analysis, difficult to interpret. Various
prospective trials have assessed the usefulness of
resistance testing for selecting the best drugs (and
avoiding the ineffective compounds) after treat-
ment failure. The contribution of resistance testing
to patient management remains at present modest,
and no superiority has been proven for any parti-
cular approach (genotypic or phenotypic) [27]. To
improve the value of resistance testing, there has
been interest in exploring the relationship with
plasma drug levels, through the calculation of a
drug–virus susceptibility inhibitory quotient (see
below).
T H E R A P E U T I C D R U G M O N I T O R I N G
A N D P H A R M A C O G E N E T I C S
There is increasing interest in therapeutic drug
monitoring, although few prospective data exist
on its usefulness in clinical management. There are
HPLC techniques described for the protease inhi-
bitors and non-nucleoside reverse transcriptase
inhibitors in use [28]. In contrast, there is no clear
interest in measuring plasma drug levels of
nucleoside analog reverse transcriptase inhibitors,
as these drugs undergo intracellular phosphoryla-
tion. Routine plasma drug level monitoring has
underscored the significant interpatient variation
in plasma drug levels, as well as the limited intra-
patient changes (for each patient, plasma drug
levels should be considered a stable phenotypic
trait) [29,30]. At the present time, there are data to
suggest the usefulness of therapeutic drug mon-
itoring in assessing compliance, and in under-
standing drug toxicity.
Figure 3 Technical approaches to assessing viral resis-
tance. It should be noted that phenotypic testing only tests
the contribution of the pol region from the patient’s virus
inserted in the context of a common viral background.
Thus neither genotypic nor phenotypic techniques cur-
rently used assess the complete viral genome or the
original viral isolate.
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The observed variation in plasma drug levels
has triggered investigation into genetic influences
in the pharmacokinetics and pharmacodynamics
of antiretroviral agents. With regard to this, two
genes, MDR1 (encoding the multidrug transporter
P-glycoprotein), and CYP2D6 (encoding the cyto-
chrome P450 isoform 2D6), have allelic variants
that modify drug levels of protease inhibitors and
non-nucleoside reverse transcriptase inhibitors
[31]. These observations open new possibilities
in predicting treatment failure or toxicity, and in
understanding the entry of drugs into pharmaco-
logic sanctuaries.
I N H I B I T O R Y Q U O T I E N T
The inhibitory quotient has been used in bacter-
iology to represent the relationship between
drug levels and phenotypic resistance. This
approach was initially developed as a method
for interpreting minimum inhibitory concentra-
tion data [32]:
Inhibitory quotient (IQ) ¼ Ctrough/IC50
where Ctrough represents the plasma drug concen-
tration at the end of the dosing interval, and IC50
the drug concentration resulting in a 50% inhibi-
tion of growth. The concept has been applied to the
field of HIV and antiretroviral agents [33], with the
following modifications:
VIQ ¼ observed Ctrough/virtual phenotype
 EC50 (wt HIV, 50% human serum)
where VIQ refers to virtual inhibitory quotient,
and EC50 represents the concentration resulting in
50% inhibition of reference wild-type virus in the
presence of a standard proportion of human serum
(to correct for drug-to-drug differences in protein
binding). EC values for reference wild-type
viruses and for various protease inhibitors are
available [34]. To date, the VIQ has been reported
to be a better predictor of response to indinavir
and lopinavir treatment than virtual phenotype
alone.
F I T N E S S A N D R E S I S T A N C E
A reduced fitness of resistant mutants has been
invoked as the basis for the immune and clinical
stability displayed by individuals infected with
drug-resistant viruses [35]. Drug-resistant strains
display a range of fitness overlapping that of
susceptible clinical isolates; however, they are
overall less infectious and replication competent
[7]. Nevertheless, viral variants with improved
fitness may evolve in the course of treatment.
Thus, continuing drug pressure could (but may
not) give rise to an increasingly replication-com-
petent, or fit, viral population over time. Methods
for characterization of viral fitness have included
comparisons of catalytic activities of mutant and
sensitive viral enzymes, analysis of infectivity,
replicative kinetic analyses, and detailed in vitro
competition between two different virus variants
mixed in a single culture, or, in vivo, by observing
the patterns of wild-type regrowth in patients
discontinuing ART. Most experiments have
employed molecular clones constructed by site-
directed mutagenesis or by insertion or recombi-
nation of mutant viral cassettes (reviewed in
Bleiber and Telenti [8]). However, the environ-
ment of the viral background may modify the
growth phenotype of recombinants. Thus, poten-
tial differences in behavior between native isolates
and their reconstructed clones should be taken into
account when analyzing data from newly avail-
able fitness assays that use recombinant viruses
[13]. The usefulness of viral fitness data for clinical
management is attracting considerable interest.
A S S E S S M E N T O F I M M U N E
R E C O V E R Y A F T E R I N I T I A T I O N
O F A R T
Currently, immune recovery is estimated from the
CD4 cell count. Increasing the count by 50 cells/
mm3, or reaching 200 CD4 cells/mm3 by 6 months
after initiation of therapy, are important predictors
of protective immunity against opportunistic dis-
eases [36]. Various factors—viremia and CD4
count at baseline, age, hepatitis C seropositivity,
CCR5 and MDR1 genotypes—influence the recov-
ery of CD4 cells [3–6,31,37]. However, several
parameters, assessing humoral or cellular immune
reconstitution, or specific responses to particular
pathogens, are available in research laboratories
[7,38–40] (Figure 1). The potential for helping in
clinical management has not been established.
There are, however, specific situations where
in-depth analysis has contributed to our understan-
ding, e.g. relapsing cases of cytomegalovirus reti-
nitis despite adequate CD4 cell count recovery by
identification of a selective absence of pathogen-
specific immunity [41].
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C O N C L U S I O N S
Currently, management of HIV disease can be
reliably effected by clinical follow-up, viral load
assessment and documentation of immune
damage by measurement of the CD4 cell popula-
tion. However, the highly individual evolution of
disease, the complexity of ART, the likelihood of
treatment failure or toxicity, and the frequent
comorbidity associated with HIV infection (e.g.
tuberculosis, hepatitis C, opportunistic diseases),
generates a moderate demand for additional
laboratory support. There are numerous techni-
ques currently available in the research setting,
some of which will probably move to clinical use
when proven to be of interest.
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